BG Medicine (BGMD +11%) ramps higher this morning after announcing the publication of two studies demonstrating the benefit of repeated galectin-3 testing as a tool in the assessment of patients with heart failure. The studies demonstrate that periodic evaluation of galectin-3 levels can help clinicians identify those at greater risk of unplanned hospital admission and cardiovascular morbidity and mortality.
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs